SUZHOU HIGHFINE BIOTECH CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 48.33 CNY | +1.49% |
|
-11.19% | -19.46% |
| Sales 2024 * | 672M 92.87M 7.31B | Sales 2025 * | 888M 123M 9.67B | Capitalization | 5.22B 722M 56.83B |
|---|---|---|---|---|---|
| Net income 2024 * | 194M 26.83M 2.11B | Net income 2025 * | 257M 35.54M 2.8B | EV / Sales 2024 * | 7.77 x |
| Net cash position 2024 * | - 0 0 | Net cash position 2025 * | - 0 0 | EV / Sales 2025 * | 5.88 x |
| P/E ratio 2024 * |
26.9
x | P/E ratio 2025 * |
20.3
x | Employees | - |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 26.27% |
More Fundamentals
* Assessed data
More news
| 1 day | +1.49% | ||
| 1 week | -11.19% | ||
| Current month | +10.57% | ||
| 1 month | +27.18% | ||
| 3 months | +8.61% | ||
| 6 months | -34.17% | ||
| Current year | -19.46% |
1 week
47.41
51.97
1 month
37.5058.22
Current year
36.5160.88
1 year
36.51118.88
3 years
36.51118.88
5 years
36.51118.88
10 years
36.51118.88
| Managers | Title | Age | Since |
|---|---|---|---|
Yong Zhu
CEO | Chief Executive Officer | 53 | 01/12/03 |
Xiao Yan Wang
DFI | Director of Finance/CFO | 44 | 31/01/04 |
Hao Yi Sun
CHM | Chairman | 46 | 30/06/11 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Qing Wang
BRD | Director/Board Member | 58 | 31/05/21 |
Yong Zhu
CEO | Chief Executive Officer | 53 | 01/12/03 |
Jie Xu
BRD | Director/Board Member | 45 | 31/10/04 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 17/05/24 | 48.33 | +1.49% | 2,699,058 |
| 16/05/24 | 47.62 | -1.22% | 1,688,193 |
| 15/05/24 | 48.21 | -3.81% | 3,378,780 |
| 14/05/24 | 50.12 | -2.66% | 2,851,854 |
| 13/05/24 | 51.49 | -5.38% | 4,006,868 |
End-of-day quote Shenzhen S.E., May 16, 2024
More quotes
Suzhou Highfine Biotech Co Ltd is a China-based company mainly engaged in the research and development (R&D), production and sales of Peptide synthesis reagents. The Company's main products include Peptide synthesis reagents such as condensation reagents, protection reagents and chiral racemic inhibition reagents, general-purpose molecular blocks and protein reagents.
Sector
Commodity Chemicals
Calendar
15/08/2024
- Q2 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
48.33
Average target price
-
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -19.46% | 723M | |
| +5.28% | 106B | |
| -5.51% | 63.94B | |
| +73.33% | 49.34B | |
| +17.24% | 39.15B | |
| +6.13% | 32.86B | |
| +12.77% | 20.29B | |
| +15.03% | 17.21B | |
| +19.06% | 15.28B | |
| +6.28% | 14.58B |
- Stock Market
- Equities
- 301393 Stock
